ABSTRACT Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are evaluated for
clinical use in chronic obstructive pulmonary disease (COPD) patients, but it is unclear whether COPD
affects BM-MSCs.
To investigate this, BM-MSCs from nine COPD patients and nine non-COPD age-matched controls were
compared with regard to immunophenotype, growth and differentiation potential, and migration capacity.
Other functional assays included the response to pro-inflammatory stimuli and inducers of the nuclear
factor (erythroid derived 2)-like 2 antioxidant response element (Nrf2-ARE) pathway, and effects on NCIH292
airway epithelial cells.
No significant differences were observed in terms of morphology, proliferation and migration, except for
increased adipocyte differentiation potential in the COPD group. Both groups were comparable regarding
mRNA expression of growth factors and inflammatory mediators, and in their...
Show moreABSTRACT Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are evaluated for
clinical use in chronic obstructive pulmonary disease (COPD) patients, but it is unclear whether COPD
affects BM-MSCs.
To investigate this, BM-MSCs from nine COPD patients and nine non-COPD age-matched controls were
compared with regard to immunophenotype, growth and differentiation potential, and migration capacity.
Other functional assays included the response to pro-inflammatory stimuli and inducers of the nuclear
factor (erythroid derived 2)-like 2 antioxidant response element (Nrf2-ARE) pathway, and effects on NCIH292
airway epithelial cells.
No significant differences were observed in terms of morphology, proliferation and migration, except for
increased adipocyte differentiation potential in the COPD group. Both groups were comparable regarding
mRNA expression of growth factors and inflammatory mediators, and in their potential to induce mRNA
expression of epidermal growth factor receptor ligands in NCI-H292 airway epithelial cells. MSCs from
COPD patients secreted more interleukin-6 in response to pro-inflammatory stimuli. Activation of the Nrf2-
ARE pathway resulted in a comparable induction of mRNA expression of four target genes, but the
expression of the NAD(P)H:quinone oxidoreductase 1 gene NQO1 was lower in MSCs from COPD patients.
The observation that MSCs from COPD patients are phenotypically and functionally comparable to
those from non-COPD controls implies that autologous MSCs can be considered for use in the setting of
clinical trials as a treatment for COPD.
Show less
